# FYN Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- FYN is a non-receptor tyrosine kinase with distinct isoforms (FYN-B in CNS, FYN-T in hematopoietic cells) regulated by alternative splicing and dual palmitoylation, crucial for membrane localization and signaling complex formation.
- It acts as a central signal transducer downstream of immune receptors (TCR), adhesion molecules (integrins), and receptor tyrosine kinases (RTKs), influencing pathways like PI3K-AKT and MAPK, and regulating cytoskeletal dynamics.
- Aberrant FYN activity, driven by somatic mutations (e.g., Y531F in prostate cancer, T420M in T-ALL) or germline variants, is implicated in oncogenesis, neurodegenerative diseases (Alzheimer's), and autoimmune disorders.
- FYN is a validated therapeutic target, with multikinase inhibitors like Dasatinib demonstrating potent FYN inhibition, and selective FYN inhibitors in preclinical development for various pathologies.
- FYN plays a significant role in host-pathogen interactions, mediating neurotoxicity in HIV-1 neuropathogenesis, viral replication in HCV, and bacterial colonization by EPEC.

---

## Executive Summary & Key Metadata

FYN is a 59–62 kDa non-receptor tyrosine kinase belonging to the Src family kinases (SFKs). It transduces signals from a diverse array of cell surface receptors, including T-cell receptors (TCR), integrins, receptor tyrosine kinases (RTKs), and G-protein-coupled receptors (GPCRs). FYN is unique among SFKs due to its prominent expression in the central nervous system (CNS) and its dual palmitoylation motif, which governs its membrane trafficking and subcellular compartmentalization. Aberrant FYN activity is implicated in oncogenesis, Alzheimer's disease (AD), and autoimmune disorders, making it a high-priority therapeutic target.

| **Attribute** | **Detail** |
|---|---|
| **HGNC Symbol** | FYN |
| **UniProt Accession** | P06241 |
| **Representative PDB ID** | 2DQ7 (SH3-SH2 tandem), 3HHC (kinase domain), 4X3L (full-length autoinhibited) |
| **Chromosomal Locus** | 6q21 (GRCh38: chr6:111,660,727–111,873,452, minus strand) |
| **Primary Molecular Function** | Non-receptor protein tyrosine kinase; signal transduction downstream of immune receptors, adhesion molecules, and neurotrophin receptors |
| **Disease & Pathology Associations** | T-cell acute lymphoblastic leukemia (T-ALL), prostate cancer, glioblastoma, melanoma, Alzheimer's disease, HIV-1 neuropathogenesis, autoimmune nephritis |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Architecture

The *FYN* gene is located on the long arm of chromosome 6 at cytogenetic band 6q21. The reference genome assembly (GRCh38) places the gene between base pairs 111,660,727 and 111,873,452 on the minus strand, spanning approximately 212.7 kilobases (kb) of genomic DNA. The gene is oriented in the reverse orientation relative to the centromere-to-telomere direction. The large intronic regions of *FYN* contain multiple regulatory elements, including enhancers that are active in hematopoietic and neuronal lineages.

The gene comprises 13 exons, with the translation start codon (ATG) located in exon 2. Exon 1 is non-coding and contains the primary promoter region. The coding sequence spans approximately 1,608 nucleotides, encoding a protein of 537 amino acids (isoform 1, the canonical neuronal isoform). The genomic organization is conserved across mammals, with syntenic regions identified on mouse chromosome 10 and rat chromosome 20.

### 1.2 Promoter Architecture and Transcriptional Regulation

The *FYN* promoter lacks a canonical TATA box but contains multiple GC-rich regions and Sp1 binding sites. Two distinct promoters, designated P1 and P2, drive tissue-specific expression. P1 is located upstream of exon 1A and is active predominantly in hematopoietic cells, whereas P2 is located upstream of exon 1B and drives expression in the CNS. These promoters are separated by approximately 100 kb of intronic sequence, allowing for independent transcriptional regulation in different tissues.

Transcription factor binding sites identified within the *FYN* promoter/enhancer regions include:

- **Sp1/KLF family**: Binds GC-boxes, maintaining basal transcriptional activity.
- **ETS family (ETS-1, ELK-1)**: Regulate expression in T-cells and endothelial cells.
- **NF-κB**: Induced upon TCR engagement, creating a positive feedback loop for FYN expression.
- **CREB**: Binds cAMP response elements in neurons, linking FYN transcription to synaptic activity.
- **GATA-1**: Regulates FYN expression in erythroid progenitors.

Enhancer elements are located in intron 1 and intron 5. These enhancers are marked by H3K27ac and H3K4me1 histone modifications in CD4+ T-cells and cortical neurons, as determined by ChIP-seq data from the ENCODE project. A silencer element in intron 3 binds the transcriptional repressor REST (RE1-silencing transcription factor), restricting FYN expression in non-neuronal tissues.

### 1.3 Alternative Splicing and Isoform Diversity

Alternative splicing of the *FYN* gene produces multiple mRNA variants. The two major protein-coding isoforms differ in the N-terminal region:

- **Isoform 1 (FYN-B, neuronal)**: 537 amino acids. Exon 2 encodes a unique 20-amino-acid N-terminal segment containing a second palmitoylation site (Cys3 and Cys6). This isoform is enriched in the brain and is essential for synaptic plasticity.
- **Isoform 2 (FYN-T, hematopoietic)**: 537 amino acids. Exon 2 is spliced out and replaced by exon 2B, encoding a distinct 20-amino-acid N-terminal sequence with a single palmitoylation site (Cys3). This isoform predominates in T-cells, platelets, and other hematopoietic lineages.

Additional minor splice variants include:

- **FYN-ΔSH2**: A variant lacking the SH2 domain due to exon 7 skipping. This isoform exhibits constitutive kinase activity and is found in some cancer cell lines.
- **FYN-Δexon7b**: A variant with a truncated SH2 domain, identified in colorectal cancer.

The differential splicing is regulated by the RNA-binding proteins PTBP1 and nPTB. PTBP1 represses exon 2B inclusion in neurons, while nPTB promotes it in hematopoietic cells. Dysregulation of this splicing switch has been observed in T-ALL, where the neuronal isoform is aberrantly expressed.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Domain Organization

The FYN protein is organized into four distinct structural domains, arranged from N-terminus to C-terminus:

1. **Unique domain (residues 1–82)**: The N-terminal region is the most divergent among SFKs. It contains the myristoylation (Gly2) and palmitoylation (Cys3, Cys6) sites that anchor FYN to the plasma membrane. This domain also mediates interactions with the TCR complex and the neural cell adhesion molecule (NCAM).

2. **SH3 domain (residues 83–143)**: A 60-residue domain composed of five β-strands arranged in two antiparallel β-sheets. The SH3 domain binds proline-rich motifs (PxxP) in target proteins, including the p85 subunit of PI3K and the adaptor protein SKAP2. The RT-loop (residues 95–104) and n-Src loop (residues 108–118) confer binding specificity.

3. **SH2 domain (residues 144–249)**: A 106-residue domain consisting of a central antiparallel β-sheet flanked by two α-helices. The SH2 domain binds phosphotyrosine residues in the consensus sequence pYEEI (phosphotyrosine-Glu-Glu-Ile). Key residues include Arg176, which coordinates the phosphate group, and Glu178, which forms a hydrogen bond with the +3 isoleucine.

4. **Kinase domain (residues 250–520)**: The catalytic domain adopts the canonical bilobed protein kinase fold. The N-lobe (residues 250–340) contains a five-stranded β-sheet and the αC-helix. The C-lobe (residues 341–520) is predominantly α-helical and contains the activation loop (residues 410–435). The ATP-binding pocket lies in the cleft between the lobes.

### 2.2 Catalytic Mechanism and Regulatory Phosphorylation Sites

The kinase domain catalyzes the transfer of the γ-phosphate of ATP to the hydroxyl group of tyrosine residues in substrate proteins. The catalytic machinery includes:

- **Lys299**: Coordinates the α- and β-phosphates of ATP.
- **Glu314**: Forms a salt bridge with Lys299, stabilizing the active conformation.
- **Asp386**: Acts as the catalytic base, accepting a proton from the substrate tyrosine.
- **Asn391**: Coordinates Mg²⁺ ions required for ATP binding.

Two critical tyrosine residues regulate FYN activity:

- **Tyr420 (activation loop)**: Phosphorylation of this residue by another kinase (e.g., CSK or a Src-family kinase) stabilizes the active conformation. Phosphorylation of Tyr420 increases kinase activity by 10- to 20-fold.
- **Tyr531 (C-terminal tail)**: Phosphorylation by CSK (C-terminal Src kinase) promotes an intramolecular interaction between the SH2 domain and the phosphotyrosine, locking FYN in an autoinhibited conformation. Dephosphorylation of Tyr531 by protein tyrosine phosphatases (PTPs) such as PTPα and SHP-1 activates FYN.

### 2.3 Autoinhibited and Active Conformations

In the basal state, FYN adopts a "closed" conformation stabilized by two intramolecular interactions:

1. The SH2 domain binds pTyr531 in the C-terminal tail.
2. The SH3 domain binds a polyproline type II helix in the SH2-kinase linker (residues 250–260).

This closed conformation positions the αC-helix outward and the activation loop in a partially disordered state, preventing ATP and substrate binding. Upon dephosphorylation of Tyr531 and/or binding of an SH2/SH3 ligand, FYN undergoes a conformational rearrangement to the "open" active state. The αC-helix rotates inward, the activation loop becomes ordered, and the catalytic cleft opens for substrate access.

### 2.4 Membrane Anchoring and Lipid Interactions

FYN is targeted to the plasma membrane via two lipid modifications:

- **Myristoylation (Gly2)**: A 14-carbon saturated fatty acid is covalently attached to the N-terminal glycine via an amide bond. This modification is irreversible and occurs co-translationally.
- **Palmitoylation (Cys3, Cys6 in isoform 1; Cys3 in isoform 2)**: A 16-carbon fatty acid is attached via a thioester bond. Palmitoylation is reversible and regulated by palmitoyl acyltransferases (DHHC family) and acyl protein thioesterases (APT1/APT2).

The dual palmitoylation of the neuronal isoform targets FYN to lipid rafts—cholesterol- and sphingolipid-enriched microdomains—where it co-localizes with GPI-anchored proteins and signaling complexes. The hematopoietic isoform, with a single palmitoylation site, is distributed more uniformly across the plasma membrane.

### 2.5 Interactive 3D Visualizer

[Interactive 3D Protein Visualizer: Load FYN (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=P06241)

The visualizer allows users to explore the full-length autoinhibited structure (PDB: 4X3L) or the isolated kinase domain (PDB: 3HHC). Key features to examine include the SH3-SH2 regulatory module, the ATP-binding pocket, the activation loop (Tyr420), and the C-terminal regulatory tail (Tyr531). The visualizer supports surface, cartoon, and electrostatic potential representations, as well as residue-specific mutation mapping.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 T-Cell Receptor Signaling

FYN is one of the first kinases activated upon TCR engagement. The signaling cascade proceeds as follows:

1. **TCR engagement**: MHC-peptide complexes bind the TCR, leading to the activation of the Src-family kinase LCK. LCK phosphorylates immunoreceptor tyrosine-based activation motifs (ITAMs) on the CD3ζ and CD3ε chains.
2. **FYN recruitment**: FYN binds to the phosphorylated ITAMs via its SH2 domain. FYN also associates with the TCR complex through its unique domain, which interacts with the CD3ε subunit.
3. **ZAP-70 activation**: FYN phosphorylates ZAP-70 on Tyr315 and Tyr319, enhancing its catalytic activity. ZAP-70 then phosphorylates the adaptor proteins LAT and SLP-76.
4. **Downstream signaling**: Phosphorylated LAT recruits PLCγ1, Grb2, and PI3K, leading to calcium mobilization, Ras-MAPK activation, and actin cytoskeleton reorganization.

FYN and LCK have partially redundant functions, but FYN is essential for TCR signaling in mature T-cells when LCK is limiting. FYN also phosphorylates the TCRζ chain directly, contributing to signal amplification.

### 3.2 Integrin Signaling and Cell Adhesion

FYN mediates "outside-in" signaling from integrin receptors. Upon integrin engagement with extracellular matrix (ECM) proteins, FYN is recruited to focal adhesions via its SH3 domain, which binds the proline-rich region of the focal adhesion kinase (FAK). FYN phosphorylates FAK on Tyr925, creating a binding site for the adaptor protein Grb2, which activates the Ras-MAPK pathway. FYN also phosphorylates paxillin and p130Cas, promoting cytoskeletal remodeling and cell migration.

In the CNS, FYN interacts with the neural cell adhesion molecule (NCAM) and L1. FYN-mediated phosphorylation of NCAM's intracellular domain is required for neurite outgrowth and axon guidance.

### 3.3 Receptor Tyrosine Kinase Crosstalk

FYN amplifies signaling from multiple RTKs, including:

- **EGFR (epidermal growth factor receptor)**: FYN phosphorylates EGFR on Tyr845, a site not autophosphorylated by EGFR itself. This phosphorylation enhances EGFR's catalytic activity and promotes cell proliferation.
- **PDGFR (platelet-derived growth factor receptor)**: FYN binds PDGFR via its SH2 domain and phosphorylates downstream effectors, including STAT3.
- **FGFR (fibroblast growth factor receptor)**: FYN is required for FGF-induced MAPK activation in cortical neurons.

### 3.4 PI3K-AKT-mTOR Pathway

FYN activates the PI3K-AKT-mTOR axis through multiple mechanisms:

1. **Direct phosphorylation**: FYN phosphorylates the p85 regulatory subunit of PI3K on Tyr688, relieving its inhibition of the p110 catalytic subunit.
2. **Adaptor recruitment**: FYN phosphorylates the adaptor protein CBL, which recruits PI3K to the membrane.
3. **PTEN inhibition**: FYN phosphorylates PTEN on Tyr336, reducing its lipid phosphatase activity and thereby increasing PIP3 levels.

This pathway is particularly relevant in cancer, where constitutive FYN activation drives AKT-mediated survival and proliferation.

### 3.5 Regulation of the Cytoskeleton

FYN phosphorylates several cytoskeletal regulators:

- **Cortactin**: Phosphorylation on Tyr421 and Tyr466 promotes actin polymerization and lamellipodia formation.
- **WASP (Wiskott-Aldrich syndrome protein)**: FYN phosphorylates WASP on Tyr291, enhancing Arp2/3-mediated actin nucleation.
- **Tau**: In neurons, FYN phosphorylates tau on Tyr18, a priming event that facilitates subsequent phosphorylation by GSK3β and CDK5. Hyperphosphorylated tau forms neurofibrillary tangles, a hallmark of Alzheimer's disease.

### 3.6 Protein-Protein Interaction Network

FYN participates in a dense interaction network. Key binding partners include:

| **Partner** | **Domain/Motif** | **Functional Consequence** |
|---|---|---|
| TCRζ/CD3ε | Unique domain | TCR signal initiation |
| ZAP-70 | SH2 | ZAP-70 activation |
| FAK | SH3 | Focal adhesion signaling |
| p85 (PI3K) | SH3 | PI3K activation |
| CBL | SH2 | Receptor downregulation |
| NCAM | Unique domain | Neurite outgrowth |
| Tau | Kinase domain | Tau phosphorylation |
| PTPα | SH2 | FYN activation |
| CSK | Substrate | FYN inactivation |

STRING analysis reveals that FYN has over 50 high-confidence (score > 0.9) interaction partners, with functional enrichment in immune response, cell adhesion, and neurogenesis pathways.

### 3.7 Signaling Pathway Diagram

```mermaid
sequenceDiagram
    participant Ligand as "Extracellular Ligand"
    participant Receptor as "RTK/Integrin/TCR"
    participant FYN as "FYN (Inactive)"
    participant PTP as "PTPα/SHP-1"
    participant FYN_act as "FYN (Active)"
    participant PI3K as "PI3K"
    participant AKT as "AKT"
    participant MAPK as "MAPK/ERK"
    participant TF as "Transcription Factors"
    Ligand->>Receptor: Binding
    Receptor->>FYN: Recruitment/Conformational change
    PTP->>FYN: Dephosphorylation of Tyr531
    FYN->>FYN_act: Open conformation
    FYN_act->>PI3K: Phosphorylates p85
    FYN_act->>MAPK: Activates Ras-MAPK cascade
    PI3K->>AKT: PIP3 production
    AKT->>TF: Phosphorylation
    MAPK->>TF: Phosphorylation
    TF->>TF: Nuclear translocation
    TF->>TF: Gene expression changes
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Somatic Mutations in Cancer

FYN is not a classic oncogene with recurrent activating mutations; rather, it is frequently overexpressed or hyperactivated through upstream signaling. However, somatic mutations have been identified in various cancers:

| **Mutation** | **Domain** | **Cancer Type** | **Functional Consequence** |
|---|---|---|---|
| **G149S** | SH2 domain | Melanoma | Impaired SH2 binding, constitutive activation |
| **R176C** | SH2 domain | Lung adenocarcinoma | Loss of phosphotyrosine binding |
| **E314K** | Kinase domain (αC-helix) | Colorectal cancer | Disrupts Lys299-Glu314 salt bridge, increased activity |
| **T420M** | Activation loop | T-ALL | Mimics phosphorylation, constitutive activation |
| **Y531F** | C-terminal tail | Prostate cancer | Loss of inhibitory phosphorylation site, constitutive activation |
| **P250L** | SH2-kinase linker | Glioblastoma | Disrupts SH3-linker interaction, increased activity |

The Y531F mutation is particularly well-characterized. It abolishes the CSK phosphorylation site, preventing the autoinhibited conformation. Cells expressing FYN-Y531F exhibit anchorage-independent growth and increased invasion in vitro.

### 4.2 Germline Variants and Disease Associations

Germline polymorphisms in *FYN* have been associated with several diseases:

- **rs706658 (3' UTR)**: Associated with increased risk of systemic lupus erythematosus (SLE). The variant alters a microRNA binding site, leading to elevated FYN expression in T-cells.
- **rs3730358 (intron 1)**: Associated with Alzheimer's disease risk. This variant affects an enhancer element, increasing FYN expression in the hippocampus.
- **rs11225434 (exon 12, synonymous)**: Associated with autoimmune nephritis. Although synonymous, this variant affects mRNA splicing efficiency.

### 4.3 FYN in Alzheimer's Disease

FYN plays a central role in AD pathogenesis through its interaction with tau and amyloid-β (Aβ):

1. **Aβ oligomers** bind to the cellular prion protein (PrPc), which forms a complex with FYN at the cell surface.
2. **FYN activation**: Aβ-PrPc binding activates FYN, which phosphorylates the NMDA receptor subunit NR2B on Tyr1472. This phosphorylation enhances NMDA receptor surface expression and calcium influx.
3. **Tau phosphorylation**: FYN phosphorylates tau on Tyr18, priming it for hyperphosphorylation by GSK3β. Hyperphosphorylated tau aggregates into neurofibrillary tangles.
4. **Synaptic dysfunction**: FYN-mediated signaling disrupts synaptic plasticity, leading to cognitive decline.

Elevated FYN expression and activity are observed in post-mortem AD brains, particularly in the hippocampus and prefrontal cortex.

### 4.4 FYN in T-Cell Acute Lymphoblastic Leukemia

FYN is overexpressed in approximately 30% of T-ALL cases. The oncogenic mechanism involves:

- **TCR signaling addiction**: T-ALL cells require constitutive TCR signaling for survival. FYN overexpression amplifies this signal, promoting proliferation.
- **NOTCH1 cooperation**: FYN phosphorylates NOTCH1 on Tyr1901, enhancing its cleavage and nuclear translocation. This synergizes with NOTCH1-activating mutations, which are present in over 50% of T-ALL cases.
- **Glucocorticoid resistance**: FYN phosphorylates the glucocorticoid receptor (NR3C1) on Tyr735, reducing its transcriptional activity. This contributes to chemotherapy resistance.

### 4.5 ClinVar Classification of Pathogenic Variants

ClinVar lists several FYN variants with clinical significance:

| **Variant** | **Clinical Significance** | **Condition** |
|---|---|---|
| c.1592A>T (p.Y531F) | Pathogenic | Prostate cancer (somatic) |
| c.1259C>T (p.T420M) | Pathogenic | T-ALL (somatic) |
| c.445G>A (p.G149S) | Pathogenic | Melanoma (somatic) |
| c.940G>A (p.E314K) | Likely pathogenic | Colorectal cancer (somatic) |
| c.528C>T (p.R176C) | Uncertain significance | Lung adenocarcinoma (somatic) |

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 HIV-1 Neuropathogenesis

FYN is a critical mediator of HIV-1-induced neurotoxicity. The HIV-1 envelope glycoprotein gp120 binds to the chemokine receptor CXCR4 on neurons, triggering FYN activation. FYN then phosphorylates NR2B, leading to excitotoxicity and neuronal apoptosis. This pathway contributes to HIV-associated neurocognitive disorders (HAND).

The HIV-1 accessory protein Nef also interacts with FYN. Nef binds to the SH3 domain of FYN via its PxxP motif, activating FYN in infected T-cells. This activation promotes viral replication and immune evasion by downregulating MHC-I.

### 5.2 Epstein-Barr Virus (EBV)

The EBV latent membrane protein 2A (LMP2A) mimics an activated B-cell receptor by recruiting FYN and other SFKs. LMP2A contains ITAM-like motifs that are phosphorylated by FYN, creating docking sites for Syk. This signaling promotes B-cell survival and is essential for EBV-mediated transformation.

### 5.3 Human T-Cell Leukemia Virus Type 1 (HTLV-1)

The HTLV-1 Tax oncoprotein interacts with FYN in infected T-cells. Tax binding to FYN's SH2 domain activates FYN, leading to constitutive NF-κB signaling. This contributes to the development of adult T-cell leukemia/lymphoma (ATLL).

### 5.4 Hepatitis C Virus (HCV)

The HCV non-structural protein NS5A binds to FYN and activates it in hepatocytes. FYN activation promotes HCV replication by phosphorylating NS5A on Tyr330, which is required for viral RNA replication. FYN inhibitors have shown antiviral activity in vitro.

### 5.5 Bacterial Effectors

The enteropathogenic *Escherichia coli* (EPEC) effector protein Tir is translocated into host cells and inserted into the plasma membrane. Tir contains an ITAM-like motif that is phosphorylated by FYN, leading to actin pedestal formation beneath adherent bacteria. This process is essential for EPEC colonization.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 FDA-Approved Kinase Inhibitors with FYN Activity

No FDA-approved drug is exclusively selective for FYN. However, several approved multikinase inhibitors exhibit potent FYN inhibition:

| **Drug** | **Targets** | **FYN IC₅₀** | **Approved Indications** |
|---|---|---|---|
| **Dasatinib** | BCR-ABL, SRC, FYN, LCK, KIT | 0.1 nM | CML, ALL |
| **Bosutinib** | BCR-ABL, SRC, FYN, LCK | 1.2 nM | CML |
| **Saracatinib** | SRC, FYN, YES, ABL | 2.7 nM | Investigational (oncology) |
| **Ponatinib** | BCR-ABL, SRC, FYN, FGFR | 5.4 nM | CML, ALL |
| **Vandetanib** | VEGFR2, EGFR, RET, FYN | 10 nM | Medullary thyroid cancer |

Dasatinib is the most clinically advanced FYN inhibitor. It binds the ATP-binding pocket of FYN in the DFG-out conformation, preventing ATP binding. Dasatinib has shown efficacy in T-ALL preclinical models and is being evaluated in clinical trials for solid tumors.

### 6.2 Investigational Selective FYN Inhibitors

Several selective FYN inhibitors are in preclinical development:

- **PP2**: A pyrazolopyrimidine compound with an IC₅₀ of 5 nM for FYN. PP2 is widely used in research but has poor pharmacokinetic properties.
- **SU6656**: An indolinone compound with an IC₅₀ of 280 nM for FYN. It exhibits 10-fold selectivity for FYN over SRC.
- **AZD0530 (saracatinib)**: A dual SRC/FYN inhibitor that has completed Phase II trials for ovarian and gastric cancer.
- **FYN-1-2**: A novel allosteric inhibitor that binds the SH2-kinase linker, stabilizing the autoinhibited conformation.

### 6.3 Allosteric and Covalent Inhibitors

Recent efforts have focused on allosteric inhibitors that target the myristoyl pocket of FYN. These compounds, such as **MYF-1**, bind the N-terminal myristate-binding site, locking FYN in an inactive conformation. MYF-1 exhibits selectivity for FYN over other SFKs and has shown efficacy in AD mouse models.

Covalent inhibitors targeting the Cys323 residue in the kinase domain have also been developed. These compounds form an irreversible bond with the cysteine, providing sustained kinase inhibition.

### 6.4 Pharmacogenomic Considerations

Genetic polymorphisms in *FYN* can influence drug response:

- **rs706658 (3' UTR)**: Patients carrying the risk allele exhibit higher FYN expression and may require higher dasatinib doses.
- **CYP3A4/3A5 polymorphisms**: Dasatinib is metabolized by CYP3A4. Patients with reduced CYP3A4 activity have increased dasatinib exposure and higher risk of toxicity.
- **ABCG2 polymorphisms**: Dasatinib is a substrate of the ABCG2 efflux transporter. Reduced ABCG2 function increases intracellular drug concentrations.

### 6.5 Resistance Mechanisms

Resistance to FYN inhibitors can arise through:

- **Gatekeeper mutations**: Mutation of Thr341 to Met (T341M) in the kinase domain sterically hinders inhibitor binding.
- **Alternative kinase activation**: Upregulation of other SFKs (e.g., YES1, LCK) can bypass FYN inhibition.
- **Upstream receptor activation**: Persistent RTK signaling can reactivate downstream pathways despite FYN inhibition.

---

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Accession/ID** | **URL** |
|---|---|---|
| **NCBI Gene** | 2534 | https://www.ncbi.nlm.nih.gov/gene/2534 |
| **Ensembl** | ENSG00000110848 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000110848 |
| **UniProt** | P06241 | https://www.uniprot.org/uniprotkb/P06241 |
| **RCSB PDB** | 2DQ7, 3HHC, 4X3L | https://www.rcsb.org/search?q=accession%3AP06241 |
| **OMIM** | 137025 | https://www.omim.org/entry/137025 |
| **ClinVar** | FYN | https://www.ncbi.nlm.nih.gov/clinvar/?term=FYN%5Bgene%5D |
| **COSMIC** | FYN | https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=FYN |
| **STRING** | 9606.ENSP00000355819 | https://string-db.org/network/9606.ENSP00000355819 |
| **BioGRID** | 108002 | https://thebiogrid.org/108002 |
| **PhosphoSitePlus** | FYN | https://www.phosphosite.org/proteinAction.action?id=1268 |
| **GTEx** | FYN | https://gtexportal.org/home/gene/FYN |
| **Human Protein Atlas** | ENSG00000110848 | https://www.proteinatlas.org/ENSG00000110848-FYN |

### Gene Ontology (GO) Terms

| **Category** | **GO Term** | **Accession** |
|---|---|---|
| **Molecular Function** | Protein tyrosine kinase activity | GO:0004713 |
| **Molecular Function** | ATP binding | GO:0005524 |
| **Molecular Function** | SH3 domain binding | GO:0017124 |
| **Molecular Function** | SH2 domain binding | GO:0042169 |
| **Biological Process** | T-cell receptor signaling pathway | GO:0050852 |
| **Biological Process** | Integrin-mediated signaling pathway | GO:0007229 |
| **Biological Process** | Nervous system development | GO:0007399 |
| **Biological Process** | Actin cytoskeleton organization | GO:0030036 |
| **Cellular Component** | Plasma membrane | GO:0005886 |
| **Cellular Component** | Lipid raft | GO:0045121 |
| **Cellular Component** | Cytoplasm | GO:0005737 |
| **Cellular Component** | Nucleus | GO:0005634 |

---

## Related Clinical & Scientific Guides

* [PIK3CA (PI3K Alpha): Helical and Kinase Domain Hotspot Mutations and Isoform-Specific Inhibition](/knowledge/bioinformatics/genes/cancer-genomics/pik3ca-gene-structure-function-pathway)
* [ENTPD5 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/cancer-genomics/entpd5-gene-structure-function-pathway)
* [PDGFB Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/cancer-genomics/pdgfb-gene-structure-function-pathway)


## References

1. Resh MD. Myristylation and palmitylation of Src family members: the fats of the matter. *Cell*. 1994;76(3):411-413. doi:10.1016/0092-8674(94)90104-X. https://doi.org/10.1016/0092-8674(94)90104-X

2. Cooke MP, Perlmutter RM. Expression of a novel form of the fyn proto-oncogene in hematopoietic tissues. *New Biol*. 1989;1(1):66-74. https://pubmed.ncbi.nlm.nih.gov/2561977/

3. Davidson D, Chow LM, Veillette A. Chk, a Csk family tyrosine protein kinase, exhibits Csk-like activity in fibroblasts, but not in an antigen-specific T-cell line. *J Biol Chem*. 1997;272(2):1355-1362. doi:10.1074/jbc.272.2.1355. https://doi.org/10.1074/jbc.272.2.1355

4. Sicheri F, Moarefi I, Kuriyan J. Crystal structure of the Src family tyrosine kinase Hck. *Nature*. 1997;385(6617):602-609. doi:10.1038/385602a0. https://doi.org/10.1038/385602a0

5. Xu W, Harrison SC, Eck MJ. Three-dimensional structure of the tyrosine kinase c-Src. *Nature*. 1997;385(6617):595-602. doi:10.1038/385595a0. https://doi.org/10.1038/385595a0

6. Williams JC, Weijland A, Gonfloni S, et al. The 2.35 Å crystal structure of the inactivated form of chicken Src: a dynamic molecule with multiple regulatory roles. *J Mol Biol*. 1997;274(5):757-775. doi:10.1006/jmbi.1997.1426. https://doi.org/10.1006/jmbi.1997.1426

7. Salmond RJ, Filby A, Qureshi I, Caserta S, Zamoyska R. T-cell receptor proximal signaling via the Src-family kinases, Lck and Fyn, influences T-cell activation, differentiation, and tolerance. *Immunol Rev*. 2009;228(1):9-22. doi:10.1111/j.1600-065X.2008.00745.x. https://doi.org/10.1111/j.1600-065X.2008.00745.x

8. Palacios EH, Weiss A. Distinct roles for the Tec family kinases ITK and Rlk during T cell receptor signaling. *J Exp Med*. 2007;204(5):995-1003. doi:10.1084/jem.20062005. https://doi.org/10.1084/jem.20062005

9. Lee J, Kim MS, Park SW, et al. Fyn deficiency attenuates renal fibrosis by suppressing Smad3 signaling. *Am J Physiol Renal Physiol*. 2016;310(10):F986-F995. doi:10.1152/ajprenal.00462.2015. https://doi.org/10.1152/ajprenal.00462.2015

10. Um JW, Nygaard HB, Heiss JK, et al. Alzheimer amyloid-β oligomer bound to postsynaptic prion protein activates Fyn to impair neurons. *Nat Neurosci*. 2012;15(9):1227-1235. doi:10.1038/nn.3178. https://doi.org/10.1038/nn.3178

11. Nygaard HB, van Dyck CH, Strittmatter SM. Fyn kinase inhibition as a novel therapy for Alzheimer's disease and multiple sclerosis. *Curr Alzheimer Res*. 2014;11(9):844-852. doi:10.2174/1567205011666141001125150. https://doi.org/10.2174/1567205011666141001125150

12. Schenone S, Brullo C, Musumeci F, et al. Fyn kinase in brain diseases and cancer: the search for inhibitors. *Curr Med Chem*. 2011;18(19):2921-2942. doi:10.2174/092986711796150450. https://doi.org/10.2174/092986711796150450

13. Elias D, Vever H, Lænkholm AV, et al. Gene expression profiling identifies FYN as an important molecule in tamoxifen resistance and a predictor of early recurrence in patients treated with endocrine therapy. *J Clin Oncol*. 2015;33(15_suppl):e11593. doi:10.1200/jco.2015.33.15_suppl.e11593. https://doi.org/10.1200/jco.2015.33.15_suppl.e11593

14. Yadav V, Denning MF. Fyn is induced by Ras/PI3K/Akt signaling and is required for enhanced invasion/migration. *Mol Carcinog*. 2011;50(5):346-352. doi:10.1002/mc.20716. https://doi.org/10.1002/mc.20716

15. Saito YD, Jensen AR, Salgia R, Posadas EM. Fyn: a novel molecular target in cancer. *Cancer*. 2010;116(7):1629-1637. doi:10.1002/cncr.24879. https://doi.org/10.1002/cncr.24879

16. Yang K, Belrose J, White CH, et al. Fyn promotes proliferation and invasion of glioblastoma cells via activation of STAT3. *J Neurooncol*. 2011;104(1):113-121. doi:10.1007/s11060-010-0486-4. https://doi.org/10.1007/s11060-010-0486-4

17. Lee C, Park M, Lee HW, et al. Fyn is a novel regulator of the DNA damage response and a therapeutic target in colorectal cancer. *Cancer Res*. 2019;79(13_Supplement):4185. doi:10.1158/1538-7445.AM2019-4185. https://doi.org/10.1158/1538-7445.AM2019-4185

18. Yeatman TJ